NucleaRDB: Extraction of mutation data from the literature

2005, NucleaRDB.

This data was extracted from Medline abstracts and full texts (when available) in an automated manner.

The table below describes the selected point mutation and provides links to other documents. The sentence(s) where the point mutation S16A was found are listed after the table.

The mutated residues are also indicated in the family sequence alignments and hyperlinked to the corresponding mutation pages.

Point mutation S16A in ANDR_HUMAN

Point mutation:	S16A
Cited point mutation:	Ser16Ala,Ser-16
Domain:	N-term
General numbering (NucleaRDB):	-
Protein:	ANDR_HUMAN (AR,DHTR, NR3C)	Swiss-Prot Cross-reference table Family page
Other point mutations / same protein	List of mutations in ANDR_HUMAN
Family alignments	3C4 Androgen (AR) 3C Glucocorticoid-like (GR,MR,PR,AR) 3 Estrogen like (ER,ERR,GR,MR,PR,AR)
Other point mutations / same position
Reference:	Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, White FM, Christian RE, Settlage RE, Shabanowitz J, Hunt DF, Weber MJ J Biol Chem 2002 Aug 9;277(32):29304-14.	Medline
Other point mutations / same article	List
Text source	HTML and PDF full texts
Validation status	True positive

Relevant sentences:

Ser-16

The estrogen receptor is phosphorylated by pp90 rsk1 on Ser-167 ; phosphorylation of Ser-167 aids in regulating the transcriptional activity of AF-1 (11 )
The Transformer TM site-directed mutagenesis kit (CLONTECH) was used to make the following point mutants: Ser-16 , -94 , -308 , -424 , and -650 to Ala
A , COS-1 cells expressing FLAG-wtAR or with Ser-16 , 94 , 308 , 424 , 650 to Ala mutations were labeled metabolically with 32P for 6 h in the presence of 5 nM R1881
Mutation of Ser-16 to Ala resulted in the loss of phosphopeptide 8 , a low stoichiometric phosphorylation
Edman degradation resulted in the loss of radioactivity at position 7 , consistent with phosphopeptide 8 containing Ser-16 (Table I )
Ser-16 is a candidate PKA / calcium calmodulin II kinase site , and Ser-81 is a candidate PKC site
It is unlikely that Ser-16 is a PKA site ; Ser-16 (phosphopeptide 8) is not up-regulated on endogenous LNCaP AR in response to FSK (Fig. 2 )

F.Horn (nucleardbcmbi.kun.nl), 21-Apr-2005